Clene enters subaward amendment for up to $8M from NIH for ALS Expanded Access Program

Clene Inc.

Amendment with Columbia University on Jan 28, 2025, extends funding for Year 2 of ACT-EAP from Sep 1, 2024 to Aug 31, 2025.
Additional $7,976,230 obligated; cumulative funding to date totals $15,324,600.
Supports CNM-Au8 treatment in ALS under the Accelerating Access to Critical Therapies for ALS Act.
Other Subaward terms from April 2024 remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.